These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38025333)

  • 1. Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience.
    Thalappil S; Khalil S; Hassini S; Al-Nesf M
    Qatar Med J; 2023; 2023(2):3. PubMed ID: 38025333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review.
    Walter G; Kalicinsky C; Warrington R; Miguel M; Reyes J; Rubin TS
    Allergy Asthma Clin Immunol; 2020; 16():34. PubMed ID: 32426003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
    Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
    J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
    Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
    Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
    [No Abstract]   [Full Text] [Related]  

  • 5. Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.
    Runken MC; Noone JM; Blanchette CM; Zacherle E; Howden R
    Am Health Drug Benefits; 2019 Oct; 12(6):294-304. PubMed ID: 31908713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
    Stein MR; Koterba A; Rodden L; Berger M
    Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
    Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
    Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
    Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H
    Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient.
    Fadeyi M; Tran T
    P T; 2013 Dec; 38(12):768-70. PubMed ID: 24391400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment.
    Eltan SB; Keskin O; Deveci MF
    North Clin Istanb; 2022; 9(3):228-234. PubMed ID: 36199862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight.
    Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I
    J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies.
    Shrestha P; Karmacharya P; Wang Z; Donato A; Joshi AY
    World Allergy Organ J; 2019 Oct; 12(10):100068. PubMed ID: 31641401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
    Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
    An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why I use subcutaneous immunoglobulin (SCIG).
    Shapiro RS
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S95-8. PubMed ID: 23264027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcomes on subcutaneous IgG in patients with humoral immunodeficiency and co-morbid bowel disease.
    Shah SN; Todoric K; Tarrant TK
    Clin Case Rep Rev; 2015 Jul; 1(7):151-152. PubMed ID: 27042340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.
    Haddad É; Barnes D; Kafal A
    Transfus Apher Sci; 2012 Jun; 46(3):315-21. PubMed ID: 22503304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.
    Bezrodnik L; Gómez Raccio A; Belardinelli G; Regairaz L; Díaz Ballve D; Seminario G; Moreira I; Riganti C; Cantisano C; Díaz H; Di Giovanni D
    J Clin Immunol; 2013 Oct; 33(7):1216-22. PubMed ID: 23846854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.